Acute renal failure and Fanconi syndrome due to deferasirox

Nephrology Dialysis Transplantation

Volumn 25, Issue 7, 2010, Pages 2376-2378

  Grangé, Steven ^a   Bertrand, Dominique M ^a   Guerrot, Dominique ^a   Eas, Florence ^b   Godin, Michel ^a  

^a Nephrology Department   (France)

^b ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

deferasirox; Fanconi syndrome; iatrogenic disease; kidney failure

Indexed keywords

CREATININE; DEFERASIROX; HYDROCHLOROTHIAZIDE; IRBESARTAN; MAGNESIUM; PHOSPHATE; POTASSIUM; URSODEOXYCHOLIC ACID; BENZOIC ACID DERIVATIVE; IRON CHELATING AGENT; TRIAZOLE DERIVATIVE;

ACUTE KIDNEY FAILURE; AGED; AMINOACIDURIA; ARTICLE; BLEEDING; CASE REPORT; CREATININE BLOOD LEVEL; DRUG WITHDRAWAL; FANCONI RENOTUBULAR SYNDROME; FUNCTIONAL ASSESSMENT; GLOMERULUS FILTRATION RATE; GLUCOSURIA; HEMOCHROMATOSIS; HUMAN; HYPERFERRITINEMIA; HYPERTENSION; HYPOKALEMIA; HYPOPHOSPHATEMIA; KIDNEY FUNCTION; MALE; PRIORITY JOURNAL; ACUTE KIDNEY INJURY; CHEMICALLY INDUCED; CHRONIC DISEASE; FANCONI SYNDROME; IRON OVERLOAD; KIDNEY; PATHOPHYSIOLOGY;

ACUTE KIDNEY INJURY; AGED; BENZOATES; CHRONIC DISEASE; FANCONI SYNDROME; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; KIDNEY; MALE; TRIAZOLES;

EID: 77954316682     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq224     Document Type: Article

References (11)

1. Lindsey WT, Olin BR. Deferasirox for transfusion-related iron overload: a clinical review. Clin Ther 2007; 29: 2154-2166
2. Taher A, El-Beshlawy A, Elalfy MS et al. Efficacy and safety of de-ferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study. Eur J Haematol 2009; 82: 458-465
3. Cappellini MD, Porter J, El-Beshlawy A et al. Tailoring iron chela-tion by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica 2010; 95: 557-566
4. Brosnahan G, Gokden N, Swaminathan S. Acute interstitial nephritis due to deferasirox: a case report. Nephrol Dial Transplant 2008; 23: 3356-3358
5. Yusuf B, McPhedran P, Brewster UC. Hypocalcemia in a dialysis patient treated with deferasirox for iron overload. Am J Kidney Dis 2008; 52: 587-590
6. Rafat C, Fakhouri F, Ribeil JA et al. Fanconi syndrome due to defer-asirox. Am J Kidney Dis 2009; 54: 931-934
7. Even-Or E, Becker-Cohen R, Miskin H. Deferasirox treatment may be associated with reversible renal Fanconi syndrome. Am J Hematol 2010; 85: 132-134
8. Gattermann N, Zoumbos N, Angelucci E et al. Impact on iron removal of dose reduction for non-progressive serum creatinine increases during treatment with the once-daily, oral iron. chelator deferasirox (Exjade, ICL670). Blood 2006; 108: 3824 abstract
9. Papassotiriou I, Margeli A, Hantzi E et al. Cystatin C levels in patients with beta-thalassemia during deferasirox treatment. Blood Cells Mol Dis 2010; 44: 152-155
10. Vanorden HE, Hagemann TM. Deferasirox\an oral agent for chronic iron overload. Ann Pharmacother 2006; 40: 1110-1117
11. Hider RC. Charge states of deferasirox-ferric iron complexes. Am J Kidney Dis 2010; 55: 614-615